Salix Pharmaceuticals (SLXP) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS
Salix Pharmaceuticals (NASDAQ:SLXP) announced its earnings results on Thursday. The company reported $1.06 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.93 by $0.13, Analyst RN reports. The company had revenue of $257.60 million for the quarter, compared to the consensus estimate of $247.29 million.
A number of analysts have recently weighed in on SLXP shares. Analysts at Roth Capital raised their price target on shares of Salix Pharmaceuticals from $106.00 to $110.00 in a research note on Friday, February 7th. On the ratings front, analysts at Zacks reiterated a “neutral” rating on shares of Salix Pharmaceuticals in a research note on Monday, January 20th. They now have a $103.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Salix Pharmaceuticals to $115.00 in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $90.80.
Shares of Salix Pharmaceuticals (NASDAQ:SLXP) traded up 1.36% on Thursday, hitting $109.75. The stock had a trading volume of 805,032 shares. Salix Pharmaceuticals has a one year low of $47.07 and a one year high of $110.93. The stock has a 50-day moving average of $99.22 and a 200-day moving average of $81.7. The company has a market cap of $6.903 billion and a price-to-earnings ratio of 64.34.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.